“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin Quarter II FY2021 Results
Mumbai, November 4, 2020: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending September 30, 2020. These unaudited results were taken on record by the Board of Directors at a meeting held today.
Financial Highlights (from Continuing Operations) – Consolidated IND-AS
Amt in INR mn
Income Statement highlights – Q2 FY2021
Balance Sheet highlights
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are very pleased with the strong recovery of our business during the quarter, demonstrated by sequential growth across all our geographies, in particular US and India. This quarter marks the start of monetization of our complex generic pipeline with the launch of Etanercept biosimilar in Europe and generic Albuterol in the US. We expect to sustain the momentum on margin improvement led by optimization efforts underway and robust growth in our key businesses.”
Consolidated Financial Results – Q2 FY2021
Consolidated Financial Results – H1 FY2021
Sales Mix
Operational Highlights
North America
Lupin’s North America sales for Q2 FY2021 were INR 13,984 mn, up 15% compared to sales of INR 12,160 mn during Q1 FY2021 and sales of INR 13,244 mn during Q2 FY2020; accounting for 37% of Lupin’s global sales.
India
Lupin’s India formulation sales for Q2 FY2021 were INR 13,323 mn, compared to sales of INR 12,854 mn during Q1 FY2021 and sales of INR 13,419 mn during Q2 FY2020; accounting for 35% of Lupin’s global sales.
During the quarter, India Region Formulation sales were flat compared to Q2 FY2020.
Lupin is now the 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2020).
Growth Markets (LATAM and APAC)
Lupin’s LATAM & APAC regions together form its Growth Markets. Growth Markets had registered sales of INR 2,918 mn for Q2 FY2021, up 8% compared to sales of INR 2,699 mn during Q1 FY2021 and sales of INR 3,030 mn during Q2 FY2020. accounting for 8% of Lupin’s global sales.
Lupin’s Brazil sales for Q2 FY2021 were BRL 59 mn, compared to BRL 55 mn during Q1 FY2021 and BRL 45 mn during Q2 FY2020.
Lupin’s Mexico sales for Q2 FY2021 were MXN 155 mn, compared to MXN 123 mn during Q1 FY2021 and MXN 167 mn during Q2 FY2020.
Lupin’s Philippines sales for Q2 FY2021 were PHP 341 mn, compared to PHP 278 mn during Q1 FY2021 and PHP 448 mn during Q2 FY2020.
Lupin’s Australia sales for Q2 FY2021 were AUD 14.4 mn, compared to AUD 12.7 mn during Q1 FY2021 and AUD 11.9 mn during Q2 FY2020.
Europe, Middle-East and Africa (EMEA)
Lupin’s EMEA sales for Q2 FY2021 were INR 3,259 mn, up 30% compared to sales of INR 2,500 mn during Q1 FY2021, and sales of INR 3,196 mn during Q2 FY2020; accounting for 9% of Lupin’s global sales.
Lupin’s South Africa sales for Q2 FY2021 were ZAR 304 mn, compared to ZAR 237 mn during Q1 FY2021 and ZAR 307 mn during Q2 FY2020.
Lupin is the 4th largest player in South Africa in the prescribed generics market (IQVIA August 2020).
Lupin’s Germany sales for Q2 FY2021 were EUR 8.1 mn, compared to EUR 7.6 mn during Q1 FY2021 and EUR 9.6 mn during Q2 FY2020.
Global API
Lupin’s Global API sales for Q2 FY2021 were INR 3,739 mn, down 9% compared to sales of INR 4,090 mn during Q1 FY2021 and sales of INR 3,052 mn during Q2 FY2020; accounting for 10% of Lupin’s global sales.
Research and Development
Investment in R&D was INR 3,843 mn (10.2% of sales) for Q2 FY2021 compared to INR 3,575 mn (10.3% of sales) for Q1 FY2021.
Lupin received approval for 4 ANDAs from the US FDA during the quarter. Cumulative ANDA filings with US FDA stood at 436 as of September 30, 2020, with the Company having received 280 approvals.
The Company now has 46 First-to-Files (FTF) filings including 16 exclusive FTF opportunities. Cumulative DMF filings stand at 198 as of September 30, 2020.
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The Company invests 10.3% of its revenues on research and development.
Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupin
| Facebook: http://www.facebook.com/LupinWorld/
For further information or queries please contact –
Head – Investor Relations and Corporate Communications
Email: arvindbothra@lupin.com
Tel: +91-22 6640 8237
General Manager – Corporate Communications
Email: manjirasharma@lupin.com
Tel: +91-22-6640 2532
Q2 FY2021 EARNINGS CONFERENCE CALL
The Company will host an Earnings Webinar at 18:00 hrs IST (20:30 hrs SST/HKT, 13:30 hrs BST, 07:30 hrs US ET) on November 05, 2020, during which the leadership team will discuss the financial performance and address questions. A transcript of the conference call will be available at our website www.lupin.com.
To Join the Earnings call (through Zoom):
Please Pre-Register by clicking the link below on your browser
https://bit.ly/34ejxFm
Please join the webinar link by 17:55 hrs IST on November 05, 2020
Instructions to join the Earnings Webinar